Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness

Triple-negative breast cancer (TNBC) is cancer that tested as negative for estrogen receptors (ER), progesterone receptors (PR), and excess human epidermal growth factor receptor 2 (HER2) protein which accounts for 15%–20% of all breast cancer cases. TNBC is considered to be a poorer prognosis than other types of breast cancer, mainly because it involves more aggressive phenotypes that are similar to stem cell–like cancer cells (cancer stem cell, CSC). Thus, targeted treatment of TNBC remains a major challenge in clinical practice. This review article surveys the latest evidence concerning the role of genomic alteration in current TNBC treatment responses, current clinical trials and potential targeting sites, CSC and drug resistance, and potential strategies targeting CSCs in TNBC. Furthermore, the role of insulin-like growth factor 1 receptor (IGF-1R) and nicotinic acetylcholine receptors (nAChR) in stemness expression, chemoresistance, and metastasis in TNBC and their relevance to potential treatments are also discussed and highlighted.

[1]  Liuting Zeng,et al.  Exploring the Regulation Mechanism of Xihuang Pill, Olibanum and β-Boswellic Acid on the Biomolecular Network of Triple-Negative Breast Cancer Based on Transcriptomics and Chemical Informatics Methodology , 2020, Frontiers in Pharmacology.

[2]  W. Tai,et al.  Brevilin A, a Natural Sesquiterpene Lactone Inhibited the Growth of Triple-Negative Breast Cancer Cells via Akt/mTOR and STAT3 Signaling Pathways , 2020, OncoTargets and therapy.

[3]  Jiaolin Bao,et al.  αO-Conotoxin GeXIVA Inhibits the Growth of Breast Cancer Cells via Interaction with α9 Nicotine Acetylcholine Receptors , 2020, Marine drugs.

[4]  A. Lakshmikuttyamma,et al.  Flavonoids and Other Polyphenols Act as Epigenetic Modifiers in Breast Cancer , 2020, Nutrients.

[5]  M. Lleonart,et al.  Insights into new mechanisms and models of cancer stem cell multidrug resistance. , 2020, Seminars in cancer biology.

[6]  Qing Zhang,et al.  Adenylosuccinate lyase hydroxylation contributes to triple negative breast cancer via the activation of cMYC , 2020, Molecular & cellular oncology.

[7]  Jenn-Kang Hwang,et al.  Membrane protein-regulated networks across human cancers , 2019, Nature Communications.

[8]  T. Aittokallio,et al.  Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets. , 2019, Cell chemical biology.

[9]  B. Xu,et al.  OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  E. Winer,et al.  Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  S. Loi,et al.  Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  P. Maín,et al.  A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses , 2019, Scientific Reports.

[13]  F. Cecconi,et al.  Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications , 2019, Cell Death & Differentiation.

[14]  A. Recasens,et al.  Targeting Cancer Cell Dormancy. , 2019, Trends in pharmacological sciences.

[15]  K. Polyak,et al.  Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. , 2019, Cancer discovery.

[16]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[17]  S. Chellappan,et al.  Regulation of Sox2 and stemness by nicotine and electronic-cigarettes in non-small cell lung cancer , 2018, Molecular Cancer.

[18]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[19]  J. Tabernero,et al.  TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence , 2018, The Journal of clinical investigation.

[20]  L. Ricci-Vitiani,et al.  Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis , 2018, Cell Death & Disease.

[21]  Evert Bosdriesz,et al.  An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential , 2018, Cell.

[22]  K. Hunter,et al.  Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence , 2018, Nature Communications.

[23]  Jen-Jung Pan,et al.  Association between Nonsteroidal Anti-Inflammatory Drugs and Colorectal Cancer: A Population-Based Case–Control Study , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[24]  G. Cassali,et al.  STAT3 as a promising chemoresistance biomarker associated with the CD44+/high/CD24‐/low/ALDH+ BCSCs‐like subset of the triple‐negative breast cancer (TNBC) cell line , 2018, Experimental cell research.

[25]  Peter Schmid,et al.  Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Hsu,et al.  IGF-1R Promotes Symmetric Self-Renewal and Migration of Alkaline Phosphatase+ Germ Stem Cells through HIF-2α-OCT4/CXCR4 Loop under Hypoxia , 2018, Stem cell reports.

[27]  G. Stark,et al.  Interferon-beta represses cancer stem cell properties in triple-negative breast cancer , 2017, Proceedings of the National Academy of Sciences.

[28]  P. Hinds.  Faculty Opinions recommendation of Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. , 2017 .

[29]  T. Ochiya,et al.  Drug Resistance Driven by Cancer Stem Cells and Their Niche , 2017, International journal of molecular sciences.

[30]  Songfa Zhang,et al.  Autophagy maintains the stemness of ovarian cancer stem cells by FOXA2. , 2017, Journal of experimental & clinical cancer research : CR.

[31]  Zheng Liu,et al.  Autophagy activation promotes bevacizumab resistance in glioblastoma by suppressing Akt/mTOR signaling pathway , 2017, Oncology letters.

[32]  H. Clevers,et al.  Cancer stem cells revisited , 2017, Nature Medicine.

[33]  M. Gasparetto,et al.  ALDHs in normal and malignant hematopoietic cells: Potential new avenues for treatment of AML and other blood cancers. , 2017, Chemico-biological interactions.

[34]  F. Sotgia,et al.  Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing anti-angiogenic therapy , 2017, OncoTarget.

[35]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[36]  A. Hauschild,et al.  Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study , 2017, BMC Cancer.

[37]  K. Pollok,et al.  Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer , 2017, npj Breast Cancer.

[38]  Tala,et al.  Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation , 2017, Cell Discovery.

[39]  A. Caicedo,et al.  Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment , 2017, Stem cells international.

[40]  Bing-he Xu,et al.  Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC) , 2017, Medicine.

[41]  L. Harris,et al.  Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Hyunggee Kim,et al.  Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting , 2017, BMB reports.

[43]  Wan-chi Lin,et al.  Autocrine IGF1 Signaling Mediates Pancreatic Tumor Cell Dormancy in the Absence of Oncogenic Drivers. , 2017, Cell reports.

[44]  P. Ghezzi,et al.  The role of autophagy in the cross-talk between epithelial-mesenchymal transitioned tumor cells and cancer stem-like cells , 2017, Molecular Cancer.

[45]  A. Schneeweiss,et al.  Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  G. Mills,et al.  Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  D. Tuveson,et al.  Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors. , 2016, Cancer research.

[48]  G. Semenza,et al.  Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. , 2016, Trends in cancer.

[49]  Dong Zhang,et al.  Defective autophagy leads to the suppression of stem-like features of CD271+ osteosarcoma cells , 2016, Journal of Biomedical Science.

[50]  J. Llovet,et al.  Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma , 2016, Gut.

[51]  A. De,et al.  An active IGF-1R-AKT signaling imparts functional heterogeneity in ovarian CSC population , 2016, Scientific Reports.

[52]  R. Agarwal,et al.  Implications of cancer stem cells in developing therapeutic resistance in oral cancer. , 2016, Oral oncology.

[53]  Yunjiao Zhang,et al.  Nanoparticle-facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cells. , 2016, Biomaterials.

[54]  Lajos Pusztai,et al.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  A. Carnero,et al.  The cancer stem-cell signaling network and resistance to therapy. , 2016, Cancer treatment reviews.

[56]  Komaraiah Palle,et al.  Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets. , 2016, Annals of translational medicine.

[57]  R. Finn,et al.  Treating cancer with selective CDK4/6 inhibitors , 2016, Nature Reviews Clinical Oncology.

[58]  L. Vermeulen,et al.  Wnt Signaling in Cancer Stem Cell Biology , 2016, Cancers.

[59]  Harold L. Moses,et al.  Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection , 2016, PloS one.

[60]  T. Efferth,et al.  Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance , 2016, Pharmaceuticals.

[61]  J. Guan,et al.  Autophagy Differentially Regulates Distinct Breast Cancer Stem-like Cells in Murine Models via EGFR/Stat3 and Tgfβ/Smad Signaling. , 2016, Cancer research.

[62]  Krister Wennerberg,et al.  Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells , 2016, Molecular Cancer.

[63]  Jiaoti Huang,et al.  All-trans retinoic acids induce differentiation and sensitize a radioresistant breast cancer cells to chemotherapy , 2016, BMC Complementary and Alternative Medicine.

[64]  I. Endo,et al.  Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype , 2016, Breast Cancer Research and Treatment.

[65]  Chi-Long Chen,et al.  Inflammation Promotes Expression of Stemness-Related Properties in HBV-Related Hepatocellular Carcinoma , 2016, PloS one.

[66]  Pauliina Kronqvist,et al.  Inhibiting Notch Activity in Breast Cancer Stem Cells by Glucose Functionalized Nanoparticles Carrying γ-secretase Inhibitors , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[67]  Aitziber L Cortajarena,et al.  Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells , 2016, Nanotechnology.

[68]  K. Machida,et al.  NANOG Metabolically Reprograms Tumor-Initiating Stem-like Cells through Tumorigenic Changes in Oxidative Phosphorylation and Fatty Acid Metabolism. , 2016, Cell metabolism.

[69]  H. Au,et al.  TGF-βI Regulates Cell Migration through Pluripotent Transcription Factor OCT4 in Endometriosis , 2015, PloS one.

[70]  G. Motalleb,et al.  The effect of nicotine on the expressions of the α7 nicotinic receptor gene and Bax and Bcl-2 proteins in the mammary gland epithelial-7 breast cancer cell line and its relationship to drug resistance , 2015, Cellular & molecular biology letters.

[71]  S. Leung,et al.  PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. , 2015, Cell metabolism.

[72]  Chundong Yu,et al.  Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma. , 2015, International journal of clinical and experimental pathology.

[73]  T. Murai.  Lipid Raft-Mediated Regulation of Hyaluronan–CD44 Interactions in Inflammation and Cancer , 2015, Front. Immunol..

[74]  D. Edwards,et al.  Mammary Stem Cells and Tumor-Initiating Cells Are More Resistant to Apoptosis and Exhibit Increased DNA Repair Activity in Response to DNA Damage , 2015, Stem cell reports.

[75]  D. N. Watkins,et al.  Hedgehog Signaling in the Maintenance of Cancer Stem Cells , 2015, Cancers.

[76]  Giorgio Mustacchi,et al.  The role of taxanes in triple-negative breast cancer: literature review , 2015, Drug design, development and therapy.

[77]  E. Aranda,et al.  Simultaneous Inhibition of EGFR/VEGFR and Cyclooxygenase-2 Targets Stemness-Related Pathways in Colorectal Cancer Cells , 2015, PloS one.

[78]  Yusuke Yamamoto,et al.  Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1 , 2015, Nature Communications.

[79]  Sanjib Basu,et al.  Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer. , 2015, The Journal of thoracic and cardiovascular surgery.

[80]  W. Huo,et al.  Prognostic value of ALDH1 expression in lung cancer: a meta-analysis. , 2015, International journal of clinical and experimental medicine.

[81]  P. Majumder,et al.  Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition , 2015, Nature Communications.

[82]  Kenneth L. Jones,et al.  Autophagy Supports Breast Cancer Stem Cell Maintenance by Regulating IL6 Secretion , 2015, Molecular Cancer Research.

[83]  T. Tung,et al.  Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression , 2015, Clinical Cancer Research.

[84]  Thomas C. Chen,et al.  Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. , 2014, Neurosurgical focus.

[85]  G. Semenza,et al.  Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells , 2014, Proceedings of the National Academy of Sciences.

[86]  P. Ray,et al.  IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells. , 2014, Cancer letters.

[87]  H. Chiou,et al.  CHRNA9 polymorphisms and smoking exposure synergize to increase the risk of breast cancer in Taiwan. , 2014, Carcinogenesis.

[88]  F. Real,et al.  Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. , 2014, Gastroenterology.

[89]  H. Ishwaran,et al.  Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways , 2014, Cell.

[90]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[91]  Eva M. Schmelz,et al.  Ovarian tumor-initiating cells display a flexible metabolism. , 2014, Experimental cell research.

[92]  Xiang Fu,et al.  ALDH1A1 overexpression is associated with the progression and prognosis in gastric cancer , 2014, BMC Cancer.

[93]  Gordon B Mills,et al.  Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.

[94]  O. Yersal,et al.  Biological subtypes of breast cancer: Prognostic and therapeutic implications. , 2014, World journal of clinical oncology.

[95]  M. Mi,et al.  Resveratrol Inhibits Breast Cancer Stem-Like Cells and Induces Autophagy via Suppressing Wnt/β-Catenin Signaling Pathway , 2014, PloS one.

[96]  K. Reue,et al.  Metabolic differences in breast cancer stem cells and differentiated progeny , 2014, Breast Cancer Research and Treatment.

[97]  M. Todaro,et al.  Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment , 2014, Cell Death and Disease.

[98]  H. Moses,et al.  Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer , 2014, Breast Cancer Research.

[99]  A. Gentles,et al.  Targeting Unique Metabolic Properties of Breast Tumor Initiating Cells , 2014, Stem cells.

[100]  W. Woodward,et al.  ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1 , 2014, Nature Cell Biology.

[101]  T. Ling,et al.  Hypoxia inducible factor 2α/insulin-like growth factor receptor signal loop supports the proliferation and Oct-4 maintenance of mouse germline stem cells. , 2014, Molecular human reproduction.

[102]  Giulia Guzzo,et al.  Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation , 2014, Oncotarget.

[103]  H. Werner,et al.  The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches , 2014, Front. Endocrinol..

[104]  D. Raha,et al.  The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. , 2014, Cancer research.

[105]  W. Willett,et al.  Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival. , 2014, Journal of the National Cancer Institute.

[106]  W. Cheng,et al.  Circulating IGF system and treatment outcome in epithelial ovarian cancer. , 2014, Endocrine-related cancer.

[107]  Saranya Chumsri,et al.  Nicotine promotes apoptosis resistance of breast cancer cells and enrichment of side population cells with cancer stem cell-like properties via a signaling cascade involving galectin-3, α9 nicotinic acetylcholine receptor and STAT3 , 2014, Breast Cancer Research and Treatment.

[108]  Ker-Chau Li,et al.  Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling , 2014, Nature Communications.

[109]  A. Krešo,et al.  Evolution of the cancer stem cell model. , 2014, Cell stem cell.

[110]  Qing‐Yu He,et al.  Id1-Induced IGF-II and Its Autocrine/Endocrine Promotion of Esophageal Cancer Progression and Chemoresistance—Implications for IGF-II and IGF-IR–Targeted Therapy , 2014, Clinical Cancer Research.

[111]  S. Barni,et al.  The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis , 2014, Breast Cancer Research and Treatment.

[112]  T. Kim,et al.  Nonsteroidal anti‐inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer , 2014, International journal of cancer.

[113]  G. Semenza,et al.  Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. , 2014, Annual review of pathology.

[114]  A. Thor,et al.  Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide , 2014, Breast Cancer Research.

[115]  Yu-mei Feng,et al.  Cancer-associated fibroblasts induce epithelial–mesenchymal transition of breast cancer cells through paracrine TGF-β signalling , 2013, British Journal of Cancer.

[116]  Yuepeng Zhou,et al.  Role of the Hypoxia-inducible factor-1 alpha induced autophagy in the conversion of non-stem pancreatic cancer cells into CD133+ pancreatic cancer stem-like cells , 2013, Cancer Cell International.

[117]  M. Bizzarri,et al.  Nicotine increases survival in human colon cancer cells treated with chemotherapeutic drugs. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[118]  P. Ye,et al.  Insulin-like growth factor-1 induces lymphangiogenesis and facilitates lymphatic metastasis in colorectal cancer. , 2013, World journal of gastroenterology.

[119]  J. Hoheisel,et al.  A mammosphere formation RNAi screen reveals that ATG4A promotes a breast cancer stem-like phenotype , 2013, Breast Cancer Research.

[120]  I. Herr,et al.  Triptolide reverses hypoxia-induced epithelial–mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation , 2013, International journal of cancer.

[121]  D. Miles,et al.  First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[122]  Laura M. Heiser,et al.  Modeling precision treatment of breast cancer , 2013, Genome Biology.

[123]  P. Bragado,et al.  TGFβ2 dictates disseminated tumour cell fate in target organs through TGFβ-RIII and p38α/β signalling , 2013, Nature Cell Biology.

[124]  G. Semenza,et al.  Role of hypoxia-inducible factors in breast cancer metastasis. , 2013, Future oncology.

[125]  M. Dewhirst,et al.  Tumor cells upregulate normoxic HIF-1α in response to doxorubicin. , 2013, Cancer research.

[126]  A. Schneeweiss,et al.  Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour. , 2013, Breast.

[127]  Bing-he Xu,et al.  Stem Cell Marker Aldehyde Dehydrogenase 1 (ALDH1)-Expressing Cells are Enriched in Triple-Negative Breast Cancer , 2013, The International journal of biological markers.

[128]  Rong Li,et al.  Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment. , 2013, Cancer letters.

[129]  H. Wildiers,et al.  Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer , 2013, Breast Cancer Research.

[130]  Andres Forero,et al.  Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer , 2013, Clinical Cancer Research.

[131]  Funda Meric-Bernstam,et al.  Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes , 2013, Clinical Cancer Research.

[132]  R. Greil,et al.  Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  S. Loi,et al.  CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer , 2013, Proceedings of the National Academy of Sciences.

[134]  D. Sipkins,et al.  LYMPHOID NEOPLASIA Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy , 2013 .

[135]  M. Trajkovic-Arsic,et al.  The role of insulin and IGF system in pancreatic cancer. , 2013, Journal of molecular endocrinology.

[136]  G. Krasnov,et al.  Deregulation of glycolysis in cancer: glyceraldehyde-3-phosphate dehydrogenase as a therapeutic target , 2013, Expert opinion on therapeutic targets.

[137]  Jyh‐cherng Yu,et al.  The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors , 2013, Breast Cancer Research.

[138]  Weiqun Peng,et al.  Identification of an ABCB1 (P‐glycoprotein)‐positive carfilzomib‐resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1 , 2013, American journal of hematology.

[139]  Jun Yao,et al.  Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. , 2013, Cancer cell.

[140]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[141]  Yu-Chao Chang,et al.  Enhancement of cancer stem-like and epithelial-mesenchymal transdifferentiation property in oral epithelial cells with long-term nicotine exposure: reversal by targeting SNAIL. , 2013, Toxicology and applied pharmacology.

[142]  A. Rustgi,et al.  Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis , 2013, British Journal of Cancer.

[143]  S. Chellappan,et al.  Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma. , 2012, Neoplasia.

[144]  M. Bizzarri,et al.  Nicotine stimulates proliferation and inhibits apoptosis in colon cancer cell lines through activation of survival pathways. , 2012, The Journal of surgical research.

[145]  A. Thompson,et al.  Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. , 2012, Cancer treatment reviews.

[146]  C. Gong,et al.  The roles of BECN1 and autophagy in cancer are context dependent , 2012, Autophagy.

[147]  Nicolò Riggi,et al.  Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. , 2012, Genes & development.

[148]  M. Wicha,et al.  Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. , 2012, Molecular cell.

[149]  A. Brivanlou,et al.  The BMP Inhibitor Coco Reactivates Breast Cancer Cells at Lung Metastatic Sites , 2012, Cell.

[150]  Anastasia Ivanova,et al.  TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  O. Inanami,et al.  Ionizing radiation induces mitochondrial reactive oxygen species production accompanied by upregulation of mitochondrial electron transport chain function and mitochondrial content under control of the cell cycle checkpoint. , 2012, Free radical biology & medicine.

[152]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[153]  V. Seshan,et al.  A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis , 2012, Cell.

[154]  Q. Sun,et al.  CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma , 2012, Journal of experimental & clinical cancer research : CR.

[155]  P. Wei,et al.  NNK Enhances Cell Migration through α7-nicotinic Acetylcholine Receptor Accompanied by Increased of Fibronectin Expression in Gastric Cancer , 2012, Annals of Surgical Oncology.

[156]  C. Gong,et al.  Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells , 2012, Oncogene.

[157]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[158]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  P. Sorger,et al.  Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.

[160]  S. Chellappan,et al.  α7 nicotinic acetylcholine receptor subunit in angiogenesis and epithelial to mesenchymal transition. , 2012, Current drug targets.

[161]  S. Batra,et al.  Nicotine/Cigarette-smoke Promotes Metastasis of Pancreatic Cancer Through α7nAChR-mediated MUC4 Up-regulation , 2012, Oncogene.

[162]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[163]  E. Morii,et al.  Reactive oxygen species and aldehyde dehydrogenase activity in Hodgkin lymphoma cells , 2012, Laboratory Investigation.

[164]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[165]  M. Ohmura,et al.  Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. , 2012, Cancer research.

[166]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[167]  Xiaohui Xu,et al.  Snail overexpression induces an epithelial to mesenchymal transition and cancer stem cell-like properties in SCC9 cells , 2012, Laboratory Investigation.

[168]  R. Schwendener,et al.  Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors , 2012, BMC Cancer.

[169]  M. Wicha,et al.  Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia , 2012, Proceedings of the National Academy of Sciences.

[170]  D. Tang,et al.  Understanding cancer stem cell heterogeneity and plasticity , 2012, Cell Research.

[171]  P. Sexton,et al.  Drug transporters in drug efficacy and toxicity. , 2012, Annual review of pharmacology and toxicology.

[172]  J. Ingels,et al.  Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer , 2012, Breast Cancer Research.

[173]  R. Kučera,et al.  [IGF1 and tumor markers in different breast cancer stages]. , 2011, Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti.

[174]  B. Martín-Castillo,et al.  Metformin: Multi-faceted protection against cancer , 2011, Oncotarget.

[175]  F. Sotgia,et al.  Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells , 2011, Cancer biology & therapy.

[176]  Hyun-Seok Kim,et al.  Sensitization of epithelial growth factor receptors by nicotine exposure to promote breast cancer cell growth , 2011, Breast Cancer Research.

[177]  E. Perez,et al.  RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[178]  Yusuke Yamamoto,et al.  An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells , 2011, Molecular Cancer.

[179]  Christopher A. Maher,et al.  A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition , 2011, The Journal of cell biology.

[180]  N. Ibrahim,et al.  Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study , 2011, Clinical Cancer Research.

[181]  Joshua M. Stuart,et al.  Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.

[182]  A. Tanimoto,et al.  Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple‐negative breast cancer , 2011, Histopathology.

[183]  P. Wei,et al.  Crosstalk between nicotine and estrogen-induced estrogen receptor activation induces α9-nicotinic acetylcholine receptor expression in human breast cancer cells , 2011, Breast Cancer Research and Treatment.

[184]  X. Bian,et al.  Mitochondrial and energy metabolism‐related properties as novel indicators of lung cancer stem cells , 2011, International journal of cancer.

[185]  Alan Mackay,et al.  Functional viability profiles of breast cancer. , 2011, Cancer discovery.

[186]  K. V. van Golen,et al.  Breast Cancer Stem Cells Survive Periods of Farnesyl-Transferase Inhibitor-Induced Dormancy by Undergoing Autophagy , 2011, Bone marrow research.

[187]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[188]  Edi Brogi,et al.  Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs , 2011, Nature Medicine.

[189]  A. Rangarajan,et al.  Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters , 2011, Cell Death and Disease.

[190]  André F. Vieira,et al.  Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype , 2011, Journal of Clinical Pathology.

[191]  A. Serafino,et al.  CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis. , 2011, Current cancer drug targets.

[192]  S. Minucci,et al.  HDACs link the DNA damage response, processing of double-strand breaks and autophagy , 2011, Nature.

[193]  P. Wei,et al.  Nicotine Promotes Cell Migration Through Alpha7 Nicotinic Acetylcholine Receptor in Gastric Cancer Cells , 2011, Annals of Surgical Oncology.

[194]  Mark Yoffe,et al.  Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.

[195]  R. Tamimi,et al.  Androgen Receptor Expression in Breast Cancer in Relation to Molecular Phenotype: Results from the Nurses’ Health Study , 2011, Modern Pathology.

[196]  Adrian V. Lee,et al.  High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy , 2010, Clinical Cancer Research.

[197]  Y. Sekino,et al.  Nicotine increases cancer stem cell population in MCF-7 cells. , 2010, Biochemical and biophysical research communications.

[198]  L. Carey,et al.  Triple-negative breast cancer: disease entity or title of convenience? , 2010, Nature Reviews Clinical Oncology.

[199]  R. Maki.  Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  W. Wong,et al.  Hypoxia-inducible factors and the response to hypoxic stress. , 2010, Molecular cell.

[201]  P. Wei,et al.  Overexpression and activation of the alpha9-nicotinic receptor during tumorigenesis in human breast epithelial cells. , 2010, Journal of the National Cancer Institute.

[202]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[203]  N. Almog.  Molecular mechanisms underlying tumor dormancy. , 2010, Cancer letters.

[204]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[205]  R. M. Simpson,et al.  Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. , 2010, Cancer research.

[206]  Arlene Chan,et al.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[207]  C. Widmann,et al.  Glucose metabolism in cancer cells , 2010, Current opinion in clinical nutrition and metabolic care.

[208]  John R Mackey,et al.  Senescence evasion by MCF-7 human breast tumor-initiating cells , 2010, Breast Cancer Research.

[209]  C. Leonetti,et al.  Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent. , 2010, Current cancer drug targets.

[210]  Lajos Pusztai,et al.  A clinically relevant gene signature in triple negative and basal-like breast cancer , 2010, Breast Cancer Research.

[211]  Y. Ho,et al.  Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[212]  Z. Szallasi,et al.  Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[213]  O. Eremin,et al.  Breast cancer chemoresistance: emerging importance of cancer stem cells. , 2010, Surgical oncology.

[214]  Mei Zhang,et al.  Selective targeting of radiation-resistant tumor-initiating cells , 2010, Proceedings of the National Academy of Sciences.

[215]  K. Pienta,et al.  GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. , 2010, Neoplasia.

[216]  Crispin J. Miller,et al.  Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene , 2010, British Journal of Cancer.

[217]  Loise M. Francisco,et al.  PD-L1 regulates the development, maintenance, and function of induced regulatory T cells , 2009, The Journal of experimental medicine.

[218]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[219]  M. Tallman,et al.  How I treat acute promyelocytic leukemia. , 2009, Blood.

[220]  D. Coppola,et al.  Nicotine Promotes Tumor Growth and Metastasis in Mouse Models of Lung Cancer , 2009, PloS one.

[221]  Kevin Struhl,et al.  Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. , 2009, Cancer research.

[222]  P. Chiao,et al.  Doxycycline induces apoptosis in PANC-1 pancreatic cancer cells. , 2009, Anticancer research.

[223]  Vincent Wai-Sun Wong,et al.  High serum interleukin‐6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B , 2009, International journal of cancer.

[224]  P. Wei,et al.  Tobacco-Specific Carcinogen Enhances Colon Cancer Cell Migration Through α7-Nicotinic Acetylcholine Receptor , 2009, Annals of surgery.

[225]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[226]  Andreas Trumpp,et al.  IFNα activates dormant haematopoietic stem cells in vivo , 2009, Nature.

[227]  Irving L. Weissman,et al.  Association of reactive oxygen species levels and radioresistance in cancer stem cells , 2009, Nature.

[228]  R. Coates,et al.  The epidemiology of triple-negative breast cancer, including race , 2009, Cancer Causes & Control.

[229]  Ling Xia,et al.  Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. , 2009, Cancer research.

[230]  G. Favre,et al.  Oncologic Trogocytosis of an Original Stromal Cells Induces Chemoresistance of Ovarian Tumours , 2008, PloS one.

[231]  Eric F. Johnson,et al.  The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. , 2008, Anticancer research.

[232]  Y. Ho,et al.  Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[233]  G. Koren,et al.  Hypoxia Enhances Tumor Stemness by Increasing the Invasive and Tumorigenic Side Population Fraction , 2008, Stem cells.

[234]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[235]  M. Volm,et al.  Prediction of Broad Spectrum Resistance of Tumors towards Anticancer Drugs , 2008, Clinical Cancer Research.

[236]  M. Simon,et al.  The role of oxygen availability in embryonic development and stem cell function , 2008, Nature Reviews Molecular Cell Biology.

[237]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[238]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[239]  H. Gómez,et al.  Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[240]  D. Balicki.  Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. , 2007, Cell stem cell.

[241]  H. Clevers,et al.  Identification of stem cells in small intestine and colon by marker gene Lgr5 , 2007, Nature.

[242]  Michael F Clarke,et al.  The biology of cancer stem cells. , 2007, Annual review of cell and developmental biology.

[243]  Harry Bartelink,et al.  Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas , 2007, Breast Cancer Research.

[244]  Sean C. Bendall,et al.  IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro , 2007, Nature.

[245]  I. Ellis,et al.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.

[246]  W. Wu,et al.  Nicotine promotes cell proliferation via alpha7-nicotinic acetylcholine receptor and catecholamine-synthesizing enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells. , 2007, Toxicology and applied pharmacology.

[247]  J. Yates,et al.  Adaptation of energy metabolism in breast cancer brain metastases. , 2007, Cancer research.

[248]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[249]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[250]  Alan Ashworth,et al.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.

[251]  M. Loeffler,et al.  Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. , 2006, The Journal of clinical investigation.

[252]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[253]  J. Moreb,et al.  RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide , 2006, Cancer Chemotherapy and Pharmacology.

[254]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[255]  J. Aguirre-Ghiso,et al.  Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. , 2006, Cancer research.

[256]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[257]  L. Tentori,et al.  Chemopotentiation by PARP inhibitors in cancer therapy. , 2005, Pharmacological research.

[258]  Jen-kun Lin,et al.  Tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces cell proliferation in normal human bronchial epithelial cells through NFκB activation and cyclin D1 up-regulation , 2005 .

[259]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[260]  P. Johnston,et al.  Molecular mechanisms of drug resistance , 2005, The Journal of pathology.

[261]  Geoffrey C Gurtner,et al.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 , 2004, Nature Medicine.

[262]  G. Semenza,et al.  Hydroxylation of HIF-1: oxygen sensing at the molecular level. , 2004, Physiology.

[263]  Carine Michiels,et al.  Physiological and pathological responses to hypoxia. , 2004, The American journal of pathology.

[264]  H. Au,et al.  Serum and endometrial markers. , 2004, Best practice & research. Clinical obstetrics & gynaecology.

[265]  L. M. Valor,et al.  Transcriptional Regulation by Activation and Repression Elements Located at the 5′-Noncoding Region of the Human α9 Nicotinic Receptor Subunit Gene* , 2003, Journal of Biological Chemistry.

[266]  G. Dontu,et al.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.

[267]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[268]  J. Foekens,et al.  RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[269]  H. Hirte,et al.  Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. , 2002, Cancer research.

[270]  B. Torok-Storb,et al.  The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. , 2002, Blood.

[271]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[272]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[273]  B. Williams,et al.  Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. , 1997, Experimental hematology.

[274]  A. S. Conner,et al.  Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo , 1996, The Journal of experimental medicine.

[275]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[276]  P. Fisher,et al.  Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting. , 2019, Advances in cancer research.

[277]  V. Jordan,et al.  Rethinking Extended Adjuvant Antiestrogen Therapy to Increase Survivorship in Breast Cancer. , 2018, JAMA oncology.

[278]  H. Schuller,et al.  Nicotine induces self-renewal of pancreatic cancer stem cells via neurotransmitter-driven activation of sonic hedgehog signalling. , 2016, European journal of cancer.

[279]  J. Unadkat,et al.  Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update , 2014, The AAPS Journal.

[280]  Yu-Chih Wu,et al.  Biology of Human Tumors Activation of IL 6 / IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT 4 / NANOG Expression , 2014 .

[281]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[282]  J. Hatina.  The dynamics of cancer stem cells. , 2012, Neoplasma.

[283]  K. Gelmon,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[284]  Y. Ho,et al.  Rapid Activation of Stat 3 and ERK 1 / 2 by Nicotine Modulates Cell Proliferation in Human Bladder Cancer Cells , 2008 .

[285]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.

[286]  P. Tsao,et al.  Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis , 2001, Nature Medicine.

[287]  B. Halliwell,et al.  Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. , 1996, The Biochemical journal.

[288]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.